Isfahan Gastroenterology and Hepatology Research Center, Isfahan University of Medical Sciences, Isfahan, Iran.
Isfahan Cardiovascular Research Center, Cardiovascular Research Institute, Isfahan University of Medical Sciences, Isfahan, Iran.
Dig Dis Sci. 2024 Apr;69(4):1345-1360. doi: 10.1007/s10620-023-08219-2. Epub 2024 Feb 15.
Increasing intestinal permeability causes chronic inflammation, which is one of the etiological factors of many diseases that presently constitute global challenges.
Considering the importance of developing therapies to eliminate the increased intestinal permeability, in this systematic review and meta-analysis, we analyze the impact of bovine colostrum (BC) on the gut barrier and its permeability.
Online databases, including PubMed, ISI Web of Science, and Scopus, were searched to find pertinent articles up to March 2022. Weighted mean difference (WMD) and 95% confidence intervals (CI) were considered as effect sizes. The random-effects model was used to pool the study results.
A total of ten articles were included in the meta-analysis. The pooled effect revealed a significant reduction in the 5-h urinary lactulose/rhamnose ratio after BC consumption [mean difference (MD): -0.24; 95% CI -0.43 to -0.04; I = 99%] and urinary lactulose/mannitol ratio (MD: -0.01; 95% CI -0.02 to -0.001; I = 29.8%). No differences were observed in the plasma intestinal fatty acid-binding protein (I-FABP) between BC and control groups (MD: 2.30; 95% CI -293.9 to 298.5; I = 92%).
BC supplementation significantly reduced intestinal permeability; however, to confirm the results, more randomized clinical trials considering different quality, dose, and duration are needed.
肠道通透性增加会导致慢性炎症,这是目前构成全球挑战的许多疾病的病因之一。
鉴于开发消除肠道通透性增加的疗法的重要性,在本次系统评价和荟萃分析中,我们分析了牛初乳(BC)对肠道屏障及其通透性的影响。
在线数据库,包括 PubMed、ISI Web of Science 和 Scopus,进行检索,以查找截至 2022 年 3 月的相关文章。加权均数差(WMD)和 95%置信区间(CI)被视为效应量。使用随机效应模型对研究结果进行汇总。
共有 10 篇文章纳入荟萃分析。汇总效应显示,BC 摄入后 5 小时尿乳果糖/鼠李糖比值显著降低[平均差(MD):-0.24;95%CI:-0.43 至 -0.04;I = 99%],尿乳果糖/甘露醇比值也显著降低(MD:-0.01;95%CI:-0.02 至 -0.001;I = 29.8%)。BC 组与对照组之间血浆肠脂肪酸结合蛋白(I-FABP)无差异(MD:2.30;95%CI:-293.9 至 298.5;I = 92%)。
BC 补充剂可显著降低肠道通透性;然而,为了确认结果,需要更多考虑不同质量、剂量和持续时间的随机临床试验。